Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC

Inclusion Criteria: 1. Age from 18 to 65 years old; 2. Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b surface antigen or positive hepatitis b virus DNA \> 0.5 year); 3. Clinical diagnosis of hepatocellular carcinoma and receive immune checkpoint inhibitors treatment. The last treatment of immune checkpoint inhibitors is less than three months from inclusion; 4. The level of hepatitis b virus DNA \< 2000 IU/mL； 5. Serum aspartate aminotransferase/alanine aminotransferase \> 20 times upper limit of normal；serum total bilirubin\>10 times upper limit of normal； 6. Prothrombin time international ratio \> 1.5; 7. Platelets \> 50\*10 E9/L; 8. Without intrahepatic bile duct dilation due to tumor progression. Exclusion Criteria: 1. Other active liver diseases; 2. Other malignancy; 3. Pregnancy or lactation; 4. Human immunodeficiency virus infection or congenital immune deficiency diseases; 5. Severe diabetes, autoimmune diseases; unstable infarction due to cardio-cerebrovascular events; other important organ dysfunctions or transplantation; 6. Active bleeding, disseminated intravascular coagulation, thrombosis, or thrombotic disease; 7. Patients received artificial liver support system treatment in one week before inclusion; 8. Patients can not follow-up; 9. Investigator considering inappropriate